About Us
Our Mission
Jeevan Therapeutics is developing next-generation bispecific nanobody therapeutics for autoimmune disease, beginning with Crohn’s disease. Our lead program is designed to address two complementary, validated biological pathways involved in disease persistence and relapse, with the goal of achieving deeper and more durable disease control.
Crohn’s is our lead indication and where we’ve built the development strategy. We see broader autoimmune potential for the approach, but we’re being disciplined about establishing the biology and product profile in Crohn’s before moving into additional indications.
Contact Us
Jeevantx: contact@jeevantx.com
